Goldman Sachs
NBIX icon

Goldman Sachs’s Neurocrine Biosciences NBIX Stock Holding History

Goldman Sachs’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,200
Closed -$402K – 6549
2025
Q2 		$402K Buy
+3,200
New +$367K ﹤0.01% 5287
2022
Q1 		– Sell
-30,000
Closed -$2.56M – 6794
2021
Q4 		$2.56M Buy
+30,000
New +$2.76M ﹤0.01% 4032
2020
Q2 		– Sell
-32,700
Closed -$2.83M – 5389
2020
Q1 		$2.83M Buy
+32,700
New +$3.2M ﹤0.01% 3071
2017
Q4 		– Sell
-92,500
Closed -$5.67M – 6545
2017
Q3 		$5.67M Buy
+92,500
New +$4.88M ﹤0.01% 3029
2017
Q1 		– Sell
-25,000
Closed -$968K – 6915
2016
Q4 		$968K Buy
+25,000
New +$1.13M ﹤0.01% 4485
2016
Q3 		– Sell
-203,100
Closed -$9.23M – 7126
2016
Q2 		$9.23M Buy
203,100
+163,800
+417% +$7.54M ﹤0.01% 2378
2016
Q1 		$1.55M Sell
39,300
-51,100
-57% -$2.03M ﹤0.01% 3707
2015
Q4 		$5.11M Sell
90,400
-215,000
-70% -$10.9M ﹤0.01% 2805
2015
Q3 		$12.2M Buy
305,400
+256,500
+525% +$12.4M ﹤0.01% 2104
2015
Q2 		$2.33M Sell
48,900
-100
-0.2% -$4.24K ﹤0.01% 3687
2015
Q1 		$1.95M Buy
+49,000
New +$1.75M ﹤0.01% 3808
2014
Q4 		– Sell
-379,500
Closed -$5.95M – 7244
2014
Q3 		$5.95M Buy
+379,500
New +$5.67M ﹤0.01% 2839
2014
Q2 		– Sell
-94,900
Closed -$1.53M – 7082
2014
Q1 		$1.53M Buy
+94,900
New +$1.62M ﹤0.01% 4251

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's NBIX Position: Q1 2026 in Review

Goldman Sachs reduced its Neurocrine Biosciences (NBIX) stake by 4.2% in Q1 2026, selling an estimated $2.04M and leaving 349,179 shares worth $46M. The position accounts for 0.01% of the portfolio, ranked #1645.

Goldman Sachs first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $166M in Q4 2017. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Goldman Sachs held 349,179 shares of Neurocrine Biosciences worth $46M as of Q1 2026.
  • Goldman Sachs sold 15,356 Neurocrine Biosciences shares in Q1 2026, an estimated $2.04M.
  • Neurocrine Biosciences made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1645 holding.
  • Goldman Sachs first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Neurocrine Biosciences position peaked at $166M in Q4 2017.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.